Literature DB >> 19494667

Secondary osteoporosis.

S F Ahmed1, M Elmantaser.   

Abstract

Secondary osteoporosis is more difficult to define in children than in adults but clearer definitions have recently been provided by the International Society for Clinical Densitometry. Whereas in adults, osteoporosis is defined on the basis of reduced bone density on scanning, in children the definition requires additional clinical parameters to be fulfilled. Secondary osteoporosis may arise either as a result of the effects of underlying disease or as a result of the treatment of such diseases (e.g. with glucocorticoids). The normal balance of bone formation and removal, both by bone modelling and remodelling, is disturbed in such a way as to alter the normal accumulation of bone that occurs during childhood. A multitude of intrinsic and extrinsic factors contributes to these processes. The underlying principles of treatment of secondary osteoporosis is, where possible, to remove the underlying cause. Where this is not possible, minimising the effects of treatment with drugs that adversely effect bone may be sufficient to eliminate any deterioration in bone quality. If this is not possible, the use of bone sparing drugs such as the bisphosphonates may be necessary whilst ensuring that attention is paid to optimising calcium and vitamin D intake and encouraging exercise and mobility. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494667     DOI: 10.1159/000223695

Source DB:  PubMed          Journal:  Endocr Dev        ISSN: 1421-7082


  12 in total

1.  Protective effect of α-lipoic acid against antimycin A cytotoxicity in MC3T3-E1 osteoblastic cells.

Authors:  Zou Lin; Zhang Guichun; Liu Lifeng; Chen Chen; Cao Xuecheng; Cai Jinfang
Journal:  Cell Stress Chaperones       Date:  2016-10-30       Impact factor: 3.667

2.  miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway.

Authors:  H Li; T Li; J Fan; T Li; L Fan; S Wang; X Weng; Q Han; R C Zhao
Journal:  Cell Death Differ       Date:  2015-07-24       Impact factor: 15.828

3.  Validity of parental recall of children's fracture: implications for investigation of childhood osteoporosis.

Authors:  R J Moon; A Lim; M Farmer; A Segaran; N M P Clarke; N C Harvey; C Cooper; J H Davies
Journal:  Osteoporos Int       Date:  2015-08-19       Impact factor: 4.507

Review 4.  Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New?

Authors:  Jason S Reich; Francis A Farraye; Sharmeel K Wasan
Journal:  Dig Dis Sci       Date:  2016-04-09       Impact factor: 3.199

Review 5.  Safety of drugs used in the treatment of osteoporosis.

Authors:  Cora McGreevy; David Williams
Journal:  Ther Adv Drug Saf       Date:  2011-08

6.  MicroRNA-433-3p promotes osteoblast differentiation through targeting DKK1 expression.

Authors:  Xiaolin Tang; Jiantao Lin; Guanhai Wang; Jianlin Lu
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

7.  Osthole improves therapy for osteoporosis through increasing autophagy of mesenchymal stem cells.

Authors:  Xuedan Zheng; Yang Yu; Binyi Shao; Ning Gan; Liang Chen; Deqin Yang
Journal:  Exp Anim       Date:  2019-06-03

Review 8.  Bone health in children and adolescents with perinatal HIV infection.

Authors:  Thanyawee Puthanakit; George K Siberry
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

9.  Serum dickkopf-1 level in postmenopausal females: correlation with bone mineral density and serum biochemical markers.

Authors:  Sahar Fathi Ahmed; Neveen Fouda; Amal Ahmed Abbas
Journal:  J Osteoporos       Date:  2013-06-27

10.  Assessing Osteoporosis in the Young Adult.

Authors:  Wong Sze Choong; Stephen Gallacher; Syed Faisal Ahmed
Journal:  Eur Endocrinol       Date:  2015-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.